Clinical Trials - December 7, 2015
Oasmia’s drug approved for clinical trials
Oasmia Pharmaceutical’s next anti-cancer drug Docecal, has been approved for clinical clients and patient recruitment will commence in January 2016. Docecal is a nanoparticle and water soluble formulation of docetaxel, one of the most commonly used anti-cancer substances in oncology today, in combination with the company’s patented technology XR-17. Docetaxel is the most active substance […]
In a new job - May 12, 2015
Oasmia Names Mikael Asp CEO
Mikael Asp has been appointed the new CEO of Oasmia pharmaceutical company. He succeeds Julian Aleksov, who has been nominated as the company’s new chairman of the board of directors. Current Board President Joel Lemon announced that he wishes to resign. Asp currently is head of quality assurance at the company and has many years […]
Agreement - June 25, 2014
Oasmia in research agreement
Swedish pharmaceutical company Oasmia Pharmaceutical AB has announced that a research agreement has been signed between Oasmia and a global pharmaceutical company. The agreement relates to the use of Oasmia’s patented nanoparticle formulation technology XR-17. The full terms of the agreement have not been disclosed at this point in time. Oasmia will initially perform tests to […]
Clinical Trials - June 16, 2014
Oasmia presents positive results from phase III study
The company’s lead human product paclical successfully meets primary objective in pivotal phase III clinical study. The data show that Paclical, which has orphan designation for epithelial ovarian cancer in the EU and in the US, met the pre-defined requirement of non-inferiority compared with Taxol. The Phase III open, randomized, multi-centre study, which included in […]
Drug Development Pharma - May 15, 2014
Green light for Oasmia’s production facility
The company’s manufacturing facility in Uppsala, Sweden, has been approved for manufacture of cytostatics by the Swedish Medical Products Agency. The approval concerns manufacture for sales in the EU. With this approval, the Medical Products Agency has confirmed that Oasmia’s manufacture of cytostatics meets the requirements of current Good Manufacturing Practice (cGMP) and Oasmia now has a […]
Drug Development Pharma - February 28, 2014
Oasmia gets FDA approval for veterinary drug
The U.S. Food and Drug Administration (FDA) has conditionally approved the Swedish pharmaceutical company’s product Paccal. Paccal Vet-CA1 is the first veterinary drug to utilize paclitaxel, a frequently used chemotherapeutics for the treatment of a wide range of cancers in humans. Paccal Vet-CA1 is specifically formulated for use in dogs for the treatment of canine skin and mammary cancers. […]
